LEVELS OF HORMONES, microRNA AND CYTOKINES IN LYMPH FROM HEALTHY AND EXPERIMENTAL BREAST CANCER
https://doi.org/10.21294/1814-4861-2016-15-5-33-39
Abstract
The involvement of hormones, microRNAs and cytokines in breast cancer pathogenesis has been well established. Lymph picks up secretory products of breast cancer cells. The purpose of the study was to evaluate the levels of hormones, microRNAs and cytokines in lymph. Wistar rats were injected with N-methyl-N-nitrosourea to induce breast cancer. The rats were subjected to either surgery alone or chemotherapy alone (cyclophosphamide, methotrexate and 5-fluorouracil). In some animals, surgery was followed by chemotherapy. The levels of follicle-stimulating hormone (FSH), prolactin, luteinizing hormone (LH), estradiol (E2) and thyroglobulin (TG), microRNA-21, microRNA-221, microRNA-222, microRNA-429 and 24 cytokines were determined. Chemotherapy was shown to result in the reduction in the levels of prolactin, thyroglobulin, FSH and estradiol. In rats with breast cancer, the expression levels of microRNA-21, microRNA-221 and microRNA-222 were increased, and the expression levels of microRNA-429 were decreased. In breast cancer rats, the levels of most cytokines were found to be increased. Correlations between the levels of cytokines, hormones, and microRNAs in lymph were identified. Differences in the expression levels of cytokines, hormones, and microRNAs in lymph with respect to treatment option were detected.
About the Authors
A. P. Lykov
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
MD, PhD, Principal Research Investigator, Laboratory of Cell Technologies, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
A. V. Kabakov
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
Junior Researcher, Laboratory of Protective System, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
N. A. Bondarenko
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
PhD, Researcher, Laboratory of Cell Technologies, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
O. V. Poveshchenko
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
MD, DSc, Head of Laboratory of Cell Technologies, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
T. V. Raiter
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
Postgraduate, Junior Researcher, Laboratory of Protective System, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
O. V. Kazakov
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
PhD, Researcher, Laboratory of Protective System, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
D. N. Strunkin
Scientific Research Institute of Clinical immunology, Russia, Novosibirsk
Russian Federation
Physician-oncologist, Scientific Research Institute of Clinical immunology (Novosibirsk, Russian Federation)
Russian Federation
Physician-oncologist, Scientific Research Institute of Clinical immunology (Novosibirsk, Russian Federation)
A. F. Poveshchenko
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Novosibirsk State Medical University, Russia, Novosibirsk
Tomsk State Pedagogical University, Russia, Novosibirsk
Russian Federation
Russian Federation
MD, DSc, Head of Protective System Laboratory, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
N. B. Orlov
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
MD, PhD, Senior Research Investigator, Laboratory of Clinical Genetic Immunity, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
V. I. Konenkov
Research Institute of Clinical and Experimental Lymphology, Russia, Novosibirsk 2, Timakova Street, 630060-Novosibirsk, Russia
Russian Federation
Russian Federation
MD, DSc, Professor, Academician of RAS, Research Institute of Clinical and Experimental Lymphology (Novosibirsk, Russian Federation)
References
1. Bernichtein S., Touraine P., Goffin V. New concepts in prolactin biology. J Endocrinol. 2010 Jul; 206 (1): 1–11. doi: 10.1677/JOE-10-0069.
2. Farhat G.N., Cummings S.R., Chlebowski R.T., Parimi N., Cauley J.A., Rohan T.E., Huang A.J., Vitolins M., Hubbell F.A., Manson J.E., Cochrane B.B., Lane D.S., Lee J.S. Sex hormone levels and risks of estrogen receptor– negative and estrogen receptor–positive breast cancers. J Natl Cancer Inst. 2011 Apr 6; 103 (7): 562–70. doi: 10.1093/jnci/djr031.
3. Szychta P., Szychta W., Gesing A., Lewinski A., Karbownik-Lewinska M. TSH receptor antibodies have predictive value for breast cancer – retrospective analysis. Thyroid Res. 2013 May 16; 6 (1): 8. doi: 10.1186/1756-6614-6-8.
4. Zhou J., Chen Y., Huang Y., Long J., Wan F., Zhang S. Serum folliclestimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer. Oncol Lett. 2013 Oct; 6 (4): 1128–1132.
5. Waters P.S., McDermott A.M., Wall D., Heneghan H.M., Miller N., Newell J., Kerin M.J., Dwyer R.M. Relationship between Circulating and Tissue microRNAs in a Murine Model of Breast Cancer PLoS One. 2012; 7 (11): e50459. doi: 10.1371/journal.pone.0050459.
6. Nicolini A., Carpi A., Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006 Oct; 17 (5): 325–37.
7. Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002; 4 (2): 65–9.
8. Raychaudhuri M., Schuster T., Buchner T., Malinowsky K., Bronger H., Schwarz- Boeger U., Hofler H., Avril S. Intratumoral heterogeneity of microRNA expression in breast cancer. J Mol Diagn. 2012 Jul; 14 (4): 376–84. doi: 10.1016/j.jmoldx.2012.01.016.
9. Hui C., Yujie F., Lijia Y., Long Y., Hongxia X., Yong Z., Jundong Z., Qianyong Z., Mantian M. MicroRNA-34 and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1- nitrosourea-induced breast carcinogenesis. Breast Cancer Res. 2012 May 22; 14 (3): R80.
Review
For citations:
Lykov A.P., Kabakov A.V., Bondarenko N.A., Poveshchenko O.V., Raiter T.V., Kazakov O.V., Strunkin D.N., Poveshchenko A.F., Orlov N.B., Konenkov V.I. LEVELS OF HORMONES, microRNA AND CYTOKINES IN LYMPH FROM HEALTHY AND EXPERIMENTAL BREAST CANCER. Siberian journal of oncology. 2016;15(5):33-39. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-5-33-39
Views:
849
Email this article 
